All In Biotech

Drug Trial Radar · NCT06306872

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABSK061 Minitablets Following Single and Multiple Oral Doses and to Assess the Effect of Administration With Soft Foods in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Feb 23, 2024

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of which is to evaluate the relative bioavailability and PK characteristics of new and old ABSK-011 capsules in a single oral dose

Conditions

  • Healthy Subjects

Interventions

  • Sequence A ABSK-011Drug

    Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).

  • Sequence B ABSK-011Drug

    Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months
  2. AUCTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months
  3. tmaxTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.